Loading
A phase 3 trial testing IDRX-42 in gastrointestinal stromal tumour, now recruiting.
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumours After Imatinib Therapy is a phase 3 interventional study registered as NCT07218926, led by GlaxoSmithKline, and recruiting on the registry. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST) After Imatinib Therapy (StrateGIST 3). Planned enrolment is 450 participants (estimated). The study started in 2025-12-03 and primary completion is expected in 2028-05-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares IDRX-42, Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Shares Imatinib-resistant GIST, Gastrointestinal stromal tumour (GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/